Your browser doesn't support javascript.
loading
The Natural History of Severe Acute Liver Injury.
Koch, David G; Speiser, J L; Durkalski, V; Fontana, R J; Davern, T; McGuire, B; Stravitz, R T; Larson, A M; Liou, I; Fix, O; Schilsky, M L; McCashland, T; Hay, J E; Murray, N; Shaikh, O S; Ganger, D; Zaman, A; Han, S B; Chung, R T; Brown, R S; Munoz, S; Reddy, K R; Rossaro, L; Satyanarayana, R; Hanje, A J; Olson, J; Subramanian, R M; Karvellas, C; Hameed, B; Sherker, A H; Lee, W M; Reuben, A.
Afiliação
  • Koch DG; Medical University of South Carolina, Charleston, South Carolina, USA.
  • Speiser JL; Medical University of South Carolina, Charleston, South Carolina, USA.
  • Durkalski V; Medical University of South Carolina, Charleston, South Carolina, USA.
  • Fontana RJ; University of Michigan, Ann Arbor, Michigan, USA.
  • Davern T; California Pacific Medical Center, San Francisco, California, USA.
  • McGuire B; University of Alabama, Birmingham, Alabama, USA.
  • Stravitz RT; Virginia Commonwealth University, Richmond, Virginia, USA.
  • Larson AM; University of Washington, Seattle, Washington, USA.
  • Liou I; University of Washington, Seattle, Washington, USA.
  • Fix O; Swedish Medical Center Seattle, Seattle, Washington, USA.
  • Schilsky ML; Yale University, New Haven, Connecticut, USA.
  • McCashland T; University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Hay JE; Mayo Clinic, Rochester, Minnesota, USA.
  • Murray N; Baylor University Medical Center, Dallas, Texas, USA.
  • Shaikh OS; University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Ganger D; Northwestern University, Evanston, Illinois, USA.
  • Zaman A; Oregon Health Sciences Center, Portland, Oregon, USA.
  • Han SB; University of California, Los Angeles, California, USA.
  • Chung RT; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Brown RS; Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.
  • Munoz S; University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Reddy KR; University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Rossaro L; University of California, Davis, California, USA.
  • Satyanarayana R; Mayo Clinic, Jacksonville, Florida, USA.
  • Hanje AJ; The Ohio State University, Columbus, Ohio, USA.
  • Olson J; University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Subramanian RM; Emory University, Atlanta, Georgia, USA.
  • Karvellas C; University of Alberta, Edmonton, Alberta, Canada.
  • Hameed B; University of California, San Francisco, California, USA.
  • Sherker AH; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
  • Lee WM; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Reuben A; Medical University of South Carolina, Charleston, South Carolina, USA.
Am J Gastroenterol ; 112(9): 1389-1396, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28440304
ABSTRACT

OBJECTIVES:

Acute liver failure (ALF) is classically defined by coagulopathy and hepatic encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis without HE, has not been carefully defined nor studied. Our aim is to describe the clinical course of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely progression to ALF, the need for liver transplantation (LT) and death.

METHODS:

386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry between 1 September 2008 through 25 October 2013, met criteria for ALI International Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10 × elevated (irrespective of bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10x elevated, and bilirubin≥3.0 mg/dl for non-APAP ALI, both groups without any discernible HE. Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate analysis, with those who recovered. A model to predict poor outcome was developed using the random forest (RF) procedure.

RESULTS:

Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP (71/179, 40%) vs. only 14/194 (7.2%) in APAP patients comprising 52% of all cases (13 cases did not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the RF procedure etiology, bilirubin, INR, APAP level and duration of jaundice were the most predictive of progression to ALF, LT, or death.

CONCLUSIONS:

A majority of ALI cases are due to APAP, 93% of whom will improve rapidly and fully recover, while non-APAP patients have a far greater risk of poor outcome and should be targeted for early referral to a liver transplant center.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Sistemas de Notificação de Reações Adversas a Medicamentos / Doença Hepática Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Sistemas de Notificação de Reações Adversas a Medicamentos / Doença Hepática Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
...